An Open-label Trial Investigating the Efficacy and Safety of a Vaginal Insert in Pregnant Women at Term

PHASE3CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

February 22, 2017

Primary Completion Date

February 24, 2018

Study Completion Date

February 24, 2018

Conditions
Cervical Ripening
Interventions
DRUG

Dinoprostone

The DVI contains 10 mg dinoprostone

Trial Locations (14)

Unknown

Yokota Maternity Hospital, Maebashi

Kitasato University Hospital, Sagamihara

Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi

Hamamatsu University Hospital, Hamamatsu

Seirei Hamamatsu General Hospital, Hamamatsu

Jichi Medical University Hospital, Shimotsuke

Itabashi Chuo Medical Center, tabashi City

University of Tsukuba Hospital, Ibaraki

Hori Hospital, Kanagawa

Rinku General Medical Center, Osaka

Juntendo University Hospital, Tokyo

Keio University Hospital, Tokyo

The University of Tokyo Hospital, Tokyo

Tokyo Metropolitan Bokutoh Hospital, Tokyo

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY

NCT03067597 - An Open-label Trial Investigating the Efficacy and Safety of a Vaginal Insert in Pregnant Women at Term | Biotech Hunter | Biotech Hunter